|drug3112||Standard (specific) therapy for COVID-19 Wiki||1.00|
|drug2148||Nigella sativa Wiki||1.00|
|drug610||COVID-19 convalescent plasma Wiki||0.45|
There is one clinical trial.
A randomized, open-label, multicenter, three-arm clinical trial to study the efficacy and safety of passive immunotherapy (convalescent plasma and anti-COVID-19 human immunoglobulin) compared to the standard treatment in Colombia.
Description: Admission to the intensive care unit with the requirement of mechanical ventilation (invasive or non-invasive) due to Acute Respiratory Distress Syndrome by COVID-19.Measure: Admission to ICU and/or mechanical ventilation Time: One year
Description: Time in the hospital from admission to discharge or death.Measure: Length of hospital stay Time: One year
Description: Neutralizing antibody (IgG) titers against COVID-19Measure: Neutralizing antibody (IgG) titers against COVID-19 Time: One year
Description: Non-serious adverse events (NSAEs) and serious adverse events (SAEs)Measure: Safety - Adverse events Time: One year
Description: Overall mortalityMeasure: Death Time: One year
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports